Atomfair

Awaiting product image

Atomfair Galidesivir BCX4430, Immucillin-A C11H15N5O3

Description Galidesivir (CAS No. 222631-44-9), also known as BCX4430 or Immucillin-A, is a synthetic nucleoside analog with the molecular formula C11H15N5O3. Its IUPAC name is (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol . This compound exhibits broad-spectrum antiviral activity, particularly against RNA viruses, by acting as an RNA-dependent RNA polymerase inhibitor. Galidesivir is a white to off-white crystalline powder with high purity (>98%) and is supplied in sealed vials under inert atmosphere to ensure stability. It is soluble in DMSO and slightly soluble in water, making it suitable for in vitro and in vivo research applications. Store at -20??C for long-term stability.

Category:
Brands:

Description

Description

Galidesivir (CAS No. 222631-44-9), also known as BCX4430 or Immucillin-A, is a synthetic nucleoside analog with the molecular formula C11H15N5O3. Its IUPAC name is (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol. This compound exhibits broad-spectrum antiviral activity, particularly against RNA viruses, by acting as an RNA-dependent RNA polymerase inhibitor. Galidesivir is a white to off-white crystalline powder with high purity (>98%) and is supplied in sealed vials under inert atmosphere to ensure stability. It is soluble in DMSO and slightly soluble in water, making it suitable for in vitro and in vivo research applications. Store at -20??C for long-term stability.

  • CAS No: 222631-44-9
  • Molecular Formula: C11H15N5O3
  • Molecular Weight: 265.27
  • Exact Mass: 265.11748936
  • Monoisotopic Mass: 265.11748936
  • IUPAC Name: (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
  • SMILES: C1=C(C2=C(N1)C(=NC=N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O
  • Synonyms: Galidesivir, 249503-25-1, IMMUCILLIN A, Immucillin-A, BCX4430

Application

Galidesivir is a promising antiviral agent studied for its efficacy against emerging RNA viruses, including Ebola, Marburg, and Zika. It functions by mimicking adenosine triphosphate (ATP), competitively inhibiting viral RNA polymerase and disrupting viral replication. Research indicates potential utility in treating severe viral hemorrhagic fevers and other infectious diseases. Preclinical studies demonstrate its broad-spectrum activity and low cytotoxicity, making it a candidate for further therapeutic development.

If you are interested or have any questions, please contact us at support@atomfair.com